Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial.

Simple item page
dc.contributor.authorBunnag, Den_US
dc.contributor.authorMalikul, Sen_US
dc.contributor.authorChittamas, Sen_US
dc.contributor.authorChindanond, Den_US
dc.contributor.authorHarinasuta, Ten_US
dc.contributor.authorFernex, Men_US
dc.contributor.authorMittelholzer, M Len_US
dc.contributor.authorKristiansen, Sen_US
dc.contributor.authorSturchler, Den_US
dc.date.accessioned2009-05-27T15:52:52Z
dc.date.available2009-05-27T15:52:52Z
dc.date.issued1992-12-01en_US
dc.descriptionThe Southeast Asian Journal of Tropical Medicine and Public Health.en_US
dc.description.abstractAt a time when Fansimef, the fixed combination of mefloquine, sulfadoxine and pyrimethamine was considered for prophylaxis of falciparum malaria, a randomized double-blind study comparing the efficacy and tolerability of Fansimef with that of Lariam (mefloquine), Fansidar, chloroquine and placebo in malaria prophylaxis was performed in Thailand from July 1987 to January 1988. The study population of 602 adult males was recruited in Pak Tongchai District, some 360 km North-East of Bangkok, where multiresistant P. falciparum is endemic. All active treatments and placebo were given once weekly for 24 weeks with doses as follows: Fansimef: 125 mg mefloquine + 250 mg sulfadoxine + 12.5 mg pyrimethamine (1 half-strength tablet); Lariam: 125 mg mefloquine (1 half-strength tablet); Fansidar: 500 mg sulfadoxine + 25 mg pyrimethamine; chloroquine; 300 mg. A loading dose of 2 half-strength tablets was given in the Fansimef group in weeks 1 and 2 and in the Lariam group in weeks 1 to 4. The incidence of acute episodes of P. falciparum per 100 person months of prophylaxis was 0.17 each in the Fansimef and the Lariam groups, 1.18 in the Fansidar group, 0.69 in the chloroquine group and 0.64 in the placebo group (differences statistically not significant). Clinically adverse events were reported by 170 subjects (Fansimef 28, Lariam 29, Fansidar 41, choroquine 43, placebo 29; differences statistically not significant). The most frequent adverse events in all groups were headache, sleepiness, dizziness and weakness.(ABSTRACT TRUNCATED AT 250 WORDS)en_US
dc.description.affiliationBangkok Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.en_US
dc.identifier.citationBunnag D, Malikul S, Chittamas S, Chindanond D, Harinasuta T, Fernex M, Mittelholzer ML, Kristiansen S, Sturchler D. Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial. The Southeast Asian Journal of Tropical Medicine and Public Health. 1992 Dec; 23(4): 777-82en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/33889
dc.language.isoengen_US
dc.source.urihttps://www.tm.mahidol.ac.th/seameo/publication.htmen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntimalarials --therapeutic useen_US
dc.subject.meshChloroquine --adverse effectsen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshMalaria, Falciparum --epidemiologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMefloquine --adverse effectsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPyrimethamine --adverse effectsen_US
dc.subject.meshSulfadoxine --adverse effectsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleFansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Southeast Asian Journal of Tropical Medicine and Public Health